BurnsAdler Extends Natulan® Partnership
with Sigma-tau S.p.A.
Charlotte, North Carolina (January 30, 2006) – BurnsAdler Pharmaceuticals, Inc. announced today that they have extended their partnership with Sigma-tau S.p.A. for the promotion and distribution of Natulan® (procarbazine hydrochloride) in Latin America and the Caribbean. Natulan® is indicated for use in combination with other anticancer drugs for the treatment of certain cancers. The product was marketed globally by Roche before being acquired by Sigma-tau and the Natulan® brand is used to commercialize the product throughout Latin America.
Carolina Cortez, Director of BurnsAdler remarked, “We are very pleased to expand our ongoing relationship with Sigma-tau for Natulan®. During the past 12 months, our sales team has been very successful in reintroducing the product throughout the Latin American region and has established relationships with more than 20 new hospitals and oncology centers. We expect our local relationships with key opinion leaders and other decision makers to bear additional fruit in 2006.”
Procarbazine was discovered in the late 1950’s during a search for monoamine oxidase (MAO) inhibitors with less serious side effects. As early as 1962, clinical trials were reported describing procarbazine’s effectiveness in Hodgkin’s disease. Procarbazine is a unique antineoplastic agent with multiple sites of action. It inhibits incorporation of small DNA precursors, as well as RNA and protein synthesis. Procarbazine is not cross-resistant with other alkylating agents.
Sigma-Tau is a leading research-based Italian pharmaceutical company with annual revenues of approximately € 620 million and over 2400 employees worldwide. Therapeutic areas in which the company’s research and development are focused include: oncology, neurology, cardiovascular, gastroenterology, metabolism and immunology. Sigma-Tau has operating subsidiaries throughout Europe and the U.S. and maintains a presence in all of the world’s major pharmaceutical markets.
BurnsAdler is a specialty pharmaceutical company that in-licenses and promotes products in Europe, South America, Mexico, Canada, Puerto Rico and the Caribbean. BurnsAdler’s portfolio currently includes products targeted for the cardiovascular, orthopaedic, oncology, CNS and critical care markets.
For additional information about this news release contact Carolina Cortez at +1.704.552.8410 Ext. 225. For additional information about BurnsAdler, please refer to the company’s website at www.burnsadler.com.